ChimeriVax™-JE + JE-VAX®
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Nov 1, 2005 → Nov 1, 2006
NCT ID
NCT00314145About ChimeriVax™-JE + JE-VAX®
ChimeriVax™-JE + JE-VAX® is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00314145. Target conditions include Japanese Encephalitis.
What happened to similar drugs?
3 of 20 similar drugs in Japanese Encephalitis were approved
Approved (3) Terminated (0) Active (17)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00314145 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis